<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035043</url>
  </required_header>
  <id_info>
    <org_study_id>EB-NAFLD-DGP-001</org_study_id>
    <nct_id>NCT05035043</nct_id>
  </id_info>
  <brief_title>Economic Burden of NAFLD</brief_title>
  <official_title>The Economic Burden of Non-Alcoholic Fatty Liver Disease Patients in Flanders, Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the economic burden of NAFLD (Non-Alcoholic-Fatty-Liver Disease) patients in&#xD;
      Belgium, Flanders by means of a bottom-up approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iMTA MCQ</measure>
    <time_frame>baseline</time_frame>
    <description>Healthcare cost measured with the iMTA MCQ (Institute for Medical Technology Assessment Medical Consumption Questionnaire). The volumes of used healthcare costs were multiplied with the unit costs of these corresponding services.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>iMTA MCQ</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient cost measured with the iMTA MCQ (Institute for Medical Technology Assessment Medical Consumption Questionnaire). The volumes of used healthcare costs were multiplied with the unit costs of these corresponding services.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5D-5L</measure>
    <time_frame>baseline</time_frame>
    <description>: Health related quality of life questionnaire EuroQol-5D-5L is used. Five levels are score in 5 dimensions. It is scaled from 0 to 100%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>NAFLD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Alcoholic Fatty Liver Disease patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Determination of the economic burden NAFLD patients</intervention_name>
    <description>Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease</description>
    <arm_group_label>NAFLD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  having NAFLD as was diagnosed by FibroScan®,&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  BMI ≥ 25 kg/m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable to give informed consent&#xD;
&#xD;
          -  &gt;70 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leen Heyens</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <phone>+32 89 32 65 05</phone>
    <email>geert.robaeys@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leen Heyens, drs.</last_name>
    <phone>+32 89 21 20 55</phone>
    <email>leen.heyens@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hasselt University</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leen Heyens, drs.</last_name>
      <phone>+32 89 21 20 55</phone>
      <email>leen.heyens@uhasselt.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Geert Robaeys</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

